B Group Inc. Buys Shares of 50,651 Assembly Biosciences, Inc. (NASDAQ:ASMB)

B Group Inc. bought a new stake in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 50,651 shares of the biopharmaceutical company's stock, valued at approximately $799,000. Assembly Biosciences makes up about 0.5% of B Group Inc.'s portfolio, making the stock its 13th biggest position. B Group Inc. owned approximately 0.80% of Assembly Biosciences as of its most recent filing with the SEC.

Other institutional investors have also recently modified their holdings of the company. JPMorgan Chase & Co. raised its holdings in Assembly Biosciences by 5,137.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company's stock valued at $53,000 after acquiring an additional 3,442 shares during the last quarter. Palumbo Wealth Management LLC purchased a new position in Assembly Biosciences in the 4th quarter valued at about $180,000. Marshall Wace LLP raised its holdings in Assembly Biosciences by 16.5% in the fourth quarter. Marshall Wace LLP now owns 14,823 shares of the biopharmaceutical company's stock valued at $234,000 after acquiring an additional 2,098 shares in the last quarter. Monimus Capital Management LP acquired a new position in Assembly Biosciences in the fourth quarter worth about $664,000. Finally, Peapod Lane Capital LLC acquired a new position in Assembly Biosciences in the fourth quarter worth $994,000. 19.92% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently weighed in on ASMB. HC Wainwright reaffirmed a "neutral" rating on shares of Assembly Biosciences in a report on Monday, March 24th. Guggenheim began coverage on shares of Assembly Biosciences in a research report on Tuesday, March 25th. They issued a "buy" rating and a $31.00 price target for the company. Finally, StockNews.com lowered shares of Assembly Biosciences from a "buy" rating to a "hold" rating in a research note on Monday, March 24th.

Assembly Biosciences Trading Up 3.4 %

ASMB stock traded up $0.34 during trading on Wednesday, reaching $10.41. 9,813 shares of the stock were exchanged, compared to its average volume of 25,709. Assembly Biosciences, Inc. has a twelve month low of $7.75 and a twelve month high of $19.93. The company has a market capitalization of $78.11 million, a P/E ratio of -1.55 and a beta of 0.65. The stock has a 50 day simple moving average of $10.73 and a 200-day simple moving average of $13.96.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last announced its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.57) EPS for the quarter, topping the consensus estimate of ($1.75) by $0.18. Assembly Biosciences had a negative return on equity of 121.46% and a negative net margin of 144.05%. The business had revenue of $7.36 million for the quarter, compared to the consensus estimate of $7.05 million. Equities analysts predict that Assembly Biosciences, Inc. will post -6.87 EPS for the current year.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.